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ABSTRACT
Protein transduction (PT) is a method for delivering
proteins into mammalian cells. PT is accomplished
by linking a small peptide tag—called a PT domain
(PTD)—to a protein of interest, which generates a
functional fusion protein that can penetrate effi-
ciently into mammalian cells. In order to study the
functions of a transcription factor (TF) of interest,
expression plasmids that encode the TF often are
transfected into mammalian cells. However, the effi-
ciency of DNA transfection is highly variable among
different cell types and is usually very low in primary
cells, stem cells and tumor cells. Zinc-finger tran-
scription factors (ZF-TFs) can be tailor-made to
target almost any gene in the human genome.
However, the extremely low efficiency of DNA trans-
fection into cancer cells, both in vivo and in vitro,
limits the utility of ZF-TFs. Here, we report on an
artificial ZF-TF that has been fused to a well-
characterized PTD from the human immunodefi-
ciency virus-1 (HIV-1) transcriptional activator
protein, Tat. This ZF-TF targeted the endogenous
promoter of the human VEGF-A gene. The PTD-
attached ZF-TF was delivered efficiently into human
cells in vitro. In addition, the VEGF-A-specific tran-
scriptional repressor retarded the growth rate of
tumor cells in a mouse xenograft experiment.
INTRODUCTION
Protein transduction is a powerful method for delivering
proteins into mammalian cells both in vivo and in vitro
(1–6). Although there are several diﬀerent protein delivery
methods, the most widely used approach is to link a small
peptide tag—called a protein transduction domain
(PTD)—to a protein of interest, which generates a fusion
protein that can penetrate eﬃciently into mammalian cells.
Dozens of diverse proteins, including transcription factors
(TFs) (7) and enzymes (5,8,9), have been delivered success-
fully into cells via protein transduction methods.
Unlike growth factors, cytokines and peptide hor-
mones, which function extracellularly, TFs do their job
inside the cells. In order to study the functions of a TF
of interest, expression plasmids that encode the TF often
are transfected into mammalian cells. The eﬃciency of
DNA transfection is highly variable among diﬀerent cell
types and is usually very low in primary cells, stem cells
and tumor cells (10,11).
Artiﬁcial TFs based on custom-designed zinc-ﬁnger
proteins (ZFPs) provide an unique opportunity to regulate
a gene of interest (12–22). Zinc-ﬁnger-transcription factors
(ZF-TFs) can be tailor-made to target almost any gene in
the human genome. For example, we and others have
produced ZF-TFs that selectively regulate diverse genes
both in vivo and in vitro. We have found, however, that
the extremely low eﬃciency of DNA transfection into
cancer cells limits the utility of ZF-TFs in cancer therapy.
Here, we report on an artiﬁcial ZF-TF that has been
fused to a well-characterized PTD from the human immu-
nodeﬁciency virus-1 (HIV-1) transcriptional activator pro-
tein, Tat. This ZF-TF was delivered eﬃciently into human
cells both in vitro and in vivo.
MATERIALS AND METHODS
Construction of plasmids
Vector constructs for the expression of ZF-TFs in mam-
malian cells are described elsewhere (14). Nucleic acids
that encode preassembled ZFPs were inserted into the
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pTAT expression plasmid (2) as follows. First, KpnI
restriction sites were added to the ZFP coding sequences
with the polymerase chain reaction (PCR) using a forward
primer that contained a KpnI site at the 50-end. The inserts
and vector (pTAT) were then prepared by digestion with
KpnI and XhoI. After ligation, the pTAT-ZFP constructs
were sequenced. When the pTAT-ZFP plasmids were con-
structed, nucleotide sequences were produced that encode
polypeptides with the following structure (from N- to
C-terminus): an ATG start codon, a hexa-histidine tag,
the HIV Tat PTD sequence, a nuclear localization signal
(NLS), and an array of ZF domains that were each fused
to an eﬀector domain isolated from TFs. We refer to these
polypeptides as PTDTAT–ZF-TF fusion proteins.
Expression and purification of PTDTAT–ZF-TF
fusion proteins
Expression vectors that encode the various transducible
chimeric PTDTAT–ZF-TF fusion proteins were trans-
formed into Escherichia coli strain BL21(DE3) pLysS,
and the resulting bacterial cells were plated onto LB-agar-
ose containing ampicillin. Single colonies of E. coli that
had been transformed with PTDTAT–ZF-TF were picked
and inoculated into selection medium. The initial culture
was inoculated into 300ml of LB selection medium and
cultivated until the culture reached an OD of 0.8. Then,
1mM IPTG was added to the culture to induce protein
expression and the cells were incubated for 2 h at 378C.
Puriﬁed preparations of the PTDTAT–ZF-TF fusion
proteins were obtained with the use of Ni-NTA agarose
(Qiagen) according to the manufacturer’s instructions.
Brieﬂy, the PTDTAT–ZF-TF—expressing BL21 cells were
subjected to centrifugation, and the cell pellets were resus-
pended in lysis buﬀer (100mM NaH2PO4, 10mM TrisCl,
8M Urea, protease inhibitor cocktail, pH 8.0) and lyzed
by ﬁve cycles of sonication on ice with a Fischer Scientiﬁc
550 Sonic Dismembrator (each cycle included 10 s of soni-
cation followed by a 30 s pause). The lysates were then
incubated with Ni-NTA agarose beads (Qiagen) for
45min, and the beads were washed twice with wash solu-
tion (100mM NaH2PO4, 10mM Tris–Cl, 8M urea, pH
6.3). Protein was eluted from the beads with elution
buﬀer (100mM NaH2PO4, 10mM Tris–Cl, 8M urea,
pH 4.5) and dialyzed against refolding solution (20mM
Tris, 1mMDTT, 0.1mM ZnCl, pH 8.0) at 48C. The dialy-
zed proteins were then concentrated using
CENTRICONTM ﬁltration, quantiﬁed with the Bradford
assay, subjected to SDS–polyacrylamide gel electrophor-
esis (SDS–PAGE), and visualized with Coomassie blue
staining. The puriﬁed protein preparations were stored
at 708C in refolding solution with 10% glycerol.
Protein transduction into HEK 293 cells and reporter assay
Human embryonic kidney (HEK) 293 cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 100U/ml penicillin, 100 mg/ml strepto-
mycin and 10% fetal bovine serum (FBS). For the lucifer-
ase assay, 104 cells/well were precultured in a 96-well plate.
Using a Lipofectamine transfection kit (Life Technologies,
Rockville, MD, USA), HEK293 cells were transfected
with 15 ng of a reporter plasmid pGL-VEGF in which
the native VEGF promoter was fused to the luciferase
gene in pGL3-basic (Promega) and 68.5 ng of internal
control reporter pRL-SV40 encoding Renilla luciferase.
Cells were then treated with diﬀerent amount of puriﬁed
PTDTAT–F435-KRAB protein. After 2 h exposure to
PTDTAT–F435-KRAB protein, cells were washed and
incubated for 24 h with fresh growth medium. The lucifer-
ase activities were measured using the Dual-LuciferaseTM
Reporter Assay System (Promega).
For the measurement of VEGF mRNA and protein,
5 104 cells/well were precultured in a 24-well plate. Cells
were treated with 250 mg of puriﬁed PTDTAT–F435-KRAB
protein for 2 h, then were washed with fresh growth
medium. Cells and culture medium were harvested at
48 h after protein transduction. Methods for VEGF
mRNA and protein analysis are described elsewhere (14).
Mouse xenograft experiments
Human colorectal cancer cells (the HM7 cell line) were
maintained in DMEM containing 10% FBS. Conﬂuent
HM7 cell cultures were harvested by brief trypsinization
(0.05% trypsin and 0.02% EDTA in Hanks’ balanced salt
solution without calcium and magnesium), washed three
times with a calcium- and magnesium-free PBS solution
and resuspended at a ﬁnal concentration of 5 106
cells/ml in serum-free DMEM.
Single-cell suspensions were conﬁrmed by phase-
contrast microscopy, and cell viability was determined
by trypan blue exclusion; only single-cell suspensions
with a viability of >90% were used. Pathogen-free
female BALB/cAnNCrj-nu athymic nude mice (4-weeks
old; Charles River Laboratories, Kanazawa, Japan) were
anesthetized, by inhalation, with diethyl ether and 5 105
HM7 colon cancer cells in 100 ml of serum-free DMEM
were inoculated subcutaneously into the mice’s dorsal
sacs. When the tumors were between 50 and 100mm3,
the animals were paired, matched into control groups
(PBS) and treatment groups [PTDTAT–ZF-TF alone, 5-
ﬂurouracil (5-FU) alone, or PTDTAT–ZF-TF plus 5-FU
(each at 35mg/kg/injection)]. Mice were treated intratu-
morally with either (i) 10 PTDTAT–ZF-TF injections (one
per day); (ii) ﬁve 5-FU injections (one per day); (iii) 10
PBS injections (one per day) or (iv) for the group that
received PTDTAT–ZF-TF and 5-FU, ﬁve PTDTAT–ZF-
TF and ﬁve 5-FU injections (one each per day for the
ﬁrst 5 days) and the ﬁve PTDTAT–ZF-TF and ﬁve PBS
injections (one each per day for the next 5 days). The mice
were surveyed regularly, tumors were measured with a
caliper and tumor volumes were determined using the fol-
lowing formula: volume=0.5 (width)2 length. Each
experimental group consisted of eight animals and a
P< 0.05 was considered to be statistically signiﬁcant.
Immunohistochemistry
After the mice were sacriﬁced, tumors were removed and
bisected as described elsewhere (23). To immunolocalize
tumor blood vessels, cryosections were stained with a mon-
oclonal rat antimouse CD31 antibody (PECAM-1; BD
PharMingen, San Diego, CA, USA) at a dilution of 1:50.
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Visualization of the antigen–antibody reaction was carried
out using an antirat immunoglobulin—horseradish perox-
idase detection kit (BD PharMingen), according to the
manufacturer’s recommendations. Vessel density was
determined by counting the stained vessels at a magniﬁca-
tion of 200.
RESULTS
VEGF-A-specific transcriptional repressors
We ﬁrst tested whether plasmids that encode ZF-TFs could
be transfected eﬃciently into cancer cells in vitro. We chose
a ZFP [termed F435 in Bae et al. (24)] that had been
designed to recognize two nearly identical 9-bp DNA
sequences in the promoter of the human VEGF-A gene.
We prepared a plasmid that encodes a ZF-TF (termed
F435-KRAB) that consists of the F435 ZFP and the
Kruppel-associated box (KRAB) transcriptional repres-
sion domain derived from the human KOX1 protein.
Noncancerous human embryonic kidney (HEK) 293 cells
and human cancer HM7 cells were transfected with the
plasmid that encodes F435-KRAB or the plasmid that
encodes the Lac Z product, b-galactosidase using Lipo-
fectamine 2000 (Invitrogen). As shown in Figure 1A and
B, F435-KRAB eﬃciently suppressed the expression of
VEGF-A in 293 cells, but not in HM7 cells. HEK 293
cells and HM7 cells transfected with the LacZ plasmid
were stained to visualize the enzyme activity (Figure 1C
and D). Greater than 90% of the transfected 293 cells
were b-galactosidase positive, but <1% of the HM7 cells
were b-galactosidase positive. These results indicate that
F435-KRAB was not able to suppress the expression of
VEGF-A in HM7 cells, because of the extremely poor eﬃ-
ciency of liposome-mediated transfection into HM7 cells.
Transduction of aVEGF-A-specific transcriptional
repressor in vitro
We then tested whether ZF-TFs could be transduced into
mammalian cells in vitro. As a ﬁrst step in generating a
transducible TF, we prepared a tripartite fusion protein
by joining the F435 ZFP to the C terminus of the 11—
amino acid PTD from the HIV-1 Tat protein, and then
fusing this construct to the N-terminus of the KRAB
domain derived from the human KOX1 protein; the result-
ing fusion protein was named PTDTat–F435-KRAB.
PTDTat–F435-KRAB was expressed in and puriﬁed from
E. coli, and then added to HEK 293 cells that had been
previously transfected with a luciferase reporter plasmid
in which the luciferase gene was under the control of the
VEGF-A promoter. As shown in Figure 2A, the PTDTat–
F435-KRAB fusion protein suppressed expression of the
luciferase reporter gene in 293 cells in a dose-dependent
manner. Puriﬁed recombinant F435-KRAB protein that
had not been attached to the Tat PTDwas used as a control
and showed no suppression of luciferase expression (data
not shown).
Next, we investigated whether the transducible TF was
able to downregulate expression of the endogenous
VEGF-A gene in HEK 293 cells. The cells were treated
with puriﬁed PTDTat–F435-KRAB for 3 h, and then incu-
bated for 48 h in fresh culture media. We then harvested
the culture supernatants and cells, and analyzed both
VEGF-A protein and mRNA concentrations. Treatment
of HEK cells with the PTDTat–F435-KRAB fusion pro-
tein reduced VEGF-A mRNA concentrations 3.1-fold (i.e.
68% suppression), compared to PBS-treated control cells
(Figure 2B). VEGF-A protein production was also
decreased by 2.7-fold (63% suppression) in the culture
treated with PTDTat–F435-KRAB, relative to the control
culture (Figure 2C).
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Figure 1. Liposome-mediated transfection of plasmids that encode either a ZF-TF or LacZ into HEK 293 cells and HM7 cancer cells. HEK 293T
cells (A) and HM7 human cancer cells (B) were transfected with a plasmid that expressed F435-KRAB or the LacZ gene product, b-galactosidase
(pcDNA3.1/His/LacZ; Invitrogen) using Lipofectamine 2000 (Invitrogen) and the amounts of secreted VEGF-A were measured by ELISA at 2 days
after transfection. The F435-KRAB-encoding plasmid eﬃciently suppressed the expression of VEGF-A in 293T cells, but not in HM7 cells. (C and
D) HEK 293T cells and HM7 cells transfected with the LacZ plasmid were stained to visualize the enzyme activity. Greater than 90% of the
transfected 293T cells were LacZ positive, but <1% of the HM7 cells were LacZ positive.
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PTDTat–F435-KRAB also eﬀectively suppressed the
expression of VEGF-A in cancer cells. VEGF-A protein
concentrations in the human colorectal cancer HM7 cell
line are several fold higher than those in the noncancerous
293 cells. HM7 cells were treated with varying amounts of
PTDTat–F435-KRAB, and VEGF-A protein concentra-
tions were measured at various time points after addition
of the transducible protein to the culture media. We
observed strong dose-dependent inhibition of VEGF-A
production by PTDTat–F435-KRAB (Figure 2D). No sig-
niﬁcant decrease in the VEGF-A protein concentrations
were observed at 12 h after treatment of the HM7 cells
with PTDTat–F435-KRAB. However, the transducible
protein yielded eﬃcient (up to 18-fold) suppression of
VEGF-A production after 24 and 48 h of incubation. In
contrast, PTDTat–F83-KRAB, which was used as a nega-
tive control, failed to suppress the expression of VEGF-A
by the cancer cells (Figure 2D). The F83 protein is a ZFP
designed to recognize the human VEGF-A promoter and
binds tightly to its target site in vitro. However, F83 is
unable to regulate expression of the endogenous VEGF-A
gene (24).
Inhibition of tumor growth in vivo by the transducible
transcriptional repressor PTDTat–F435-KRAB
We next investigated whether the VEGF-A-speciﬁc
PTDTat–F435-KRAB fusion protein could inhibit the
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Figure 2. Regulation of luciferase reporter activity by PTDTAT–F435-KRAB. (A) HEK 293 cells were cotransfected with 15 ng of pGL-VEGF and
68.5 ng of the Renilla luciferase expression plasmid pRL-SV40. The cells were then treated with the indicated amount of puriﬁed PTDTAT–F435-
KRAB 24 h after transfection. Luciferase activity was measured 24 h after protein transduction. (B) Repression of endogenous VEGF-A at the
mRNA level. HEK 293 cells (105 cells/24-well plate) were treated with either PBS or PTDTAT–F435-KRAB (250 mg) for 2 h, then the culture medium
was replaced with fresh growth medium (DMEM, 10% FBS). VEGF-A mRNA was analyzed by RT–PCR using speciﬁc primers. The amount of
VEGF mRNA was normalized to the amount of GAPDH mRNA from the same RT product, then relative VEGF mRNA amounts from PTDTAT–
F435-KRAB-treated cells were represented as values compared to normalized values from control PBS-treated cells. (C) From the same experiments
described in (B), the culture medium at 24 h after transduction with either PBS (control) or eﬀector (PTDTAT–F435-KRAB) was harvested. The
amount of secreted VEGF-A protein was measured by ELISA with an antibody speciﬁc to human VEGF-A. (D) Dose-dependent repression of
VEGF-A protein expression by PTDTAT–F435-KRAB. HEK293F cells were treated with various amounts of PTDTAT–F435-KRAB for 2 h, and
then the culture medium was replaced with fresh growth medium. Culture supernatants were harvested at the indicated times (white bar, after 12 h;
gray bar, after 24 and black bar, after 48 h). Secreted VEGF-A amounts were measured by ELISA. TAT-F83-KRAB was used as a negative control.
All of the results in Figure 1 are the mean values and SEs of three independent experiments.
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formation of new blood vessels around tumor cells and
retard the growth rate of tumor cells in vivo. HM7 cells
were injected into the dorsal sacs of nude mice (BALB/c)
and allowed to grow for 7 days. The animals were then
divided into the following four treatment groups: group 1,
treatment with PTDTat–F435-KRAB alone [10 daily intra-
tumoral (IT) injections]; group 2, treatment with 5-FU (an
antineoplastic drug) alone (5 daily IT injections); group 3,
treatment with PTDTat–F435-KRAB and 5-FU (5 daily IT
injections with PTDTat–F435-KRAB and 5-FU, followed
by 5 daily IT injections with PBS) and group 4, treatment
with PBS (control) (10 daily IT injections).
Tumors injected with PTDTat–F435-KRAB alone
showed a signiﬁcant reduction in size compared to PBS-
treated control tumors (Figure 3). The VEGF-targeting
protein showed 34 and 27% reduction in the average
tumor volume compared to control at days 14 and 17,
respectively, after the ﬁrst injection (P< 0.05). Similarly,
at day 30, the average tumor volume of the protein—
treated mice was only 67% of that of PBS-treated mice
(P< 0.05). Thus, the transducible TF alone inhibited
tumor growth by 33% at day 30. 5-FU alone strongly
inhibited tumor growth by 70% compared to the PBS-trea-
ted control group. The combination treatment of both
5-FU and PTDTat–F435-KRAB led to an 83% reduction
in tumor size, relative to the PBS-treated control group.
[However, the diﬀerence between the antitumor eﬀect of
5-FU treatment and that of the combination treatment
was not statistically signiﬁcant (P=0.058).] These results
suggest that the VEGF-A targeting, synthetic transducible
TF functions as an antitumor agent and may enhance the
response of tumor cells to 5-FU treatment.
To conﬁrm the mechanism of the antitumor activity of
PTDTat–F435-KRAB, we carried out immunohistochem-
ical analyses. After the mice were sacriﬁced, the tumors
were removed and bisected. Blood vessels were visualized
by staining tumor cryosections with a monoclonal rat
antimouse CD31 antibody. As shown in Figure 4, both
the number and size of CD31-positive blood vessels were
decreased signiﬁcantly (43%) in tumor sections from mice
treated with PTDTat–F435-KRAB, relative to PBS con-
trols. 5-FU treatment alone did not elicit a reduction of
CD31-positive vessels. 5-FU is a potent inhibitor of thy-
midylate synthase and does not inhibit angiogenesis. The
small reduction of CD31-positive vessels in animals trea-
ted with 5-FU in our results is statistically insigniﬁcant.
In contrast, the combination treatment of 5-FU and
PTDTat–F435-KRAB strongly inhibited the formation of
blood vessels; microvessel density was reduced by 64% in
response to the combination treatment, compared to the
PBS control group (P< 0.01).
DISCUSSION
Artiﬁcial TFs constructed by assembling ZFDNA-binding
modules and appropriate transcriptional eﬀector domains
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Figure 3. Tumor growth inhibition in xenograft mice. Human colo-
rectal cancer cells (HM7 cell line) were xenografted into nude mice.
The mice either received no treatment (control) or were treated by
injection with PTDTAT–F435-KRAB (ZFP) alone; 5-FU in combina-
tion with PTDTAT–F435-KRAB (ZFP+5-FU) or 5-FU alone at the
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Figure 4. Immunohistochemistry of tumor blood vessels. Cryosections of tumors from xenografted mice described in Figure 2 were stained to
visualize CD31 (PECAM-1). Angiogenesis indices were determined by calculating vessel densities from at least three cryosections prepared from mice
of each group. The diﬀerences between the angiogenesis index of tumors from control (PBS-treated) mice and the angiogenesis indices of tumors
from mice treated with PTDTAT–F435-KRAB (ZFP) or PTDTAT–F435-KRAB and 5-FU (ZFP+5-FU) were statistically signiﬁcant (++)
(ANOVA test, P< 0.01). The angiogenesis indices shown are the mean values and SE of three independent experiments.
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have been developed for the regulation of a variety of
viral and endogenous mammalian genes (12, 14–22,24).
In these studies, ZF-TFs of choice have been delivered to
target cells via DNA transfection or viral vectors, methods
that have limitations for use in research and medicine. The
DNA delivery eﬃciency of liposome-mediated transfection
is highly dependent on cell types and usually very low in
primary cultures and certain tumor cells (10,11). Naked
DNA transfection, while ineﬃcient, is often used in
animal experiments and clinical studies in humans, largely
because of its favorable safety proﬁle (25). Safety concerns
also make the use of viral vectors in clinical trials diﬃcult,
if not impossible. PT is an alternative method with a few
important advantages. Various peptide tags and protein
domains have been developed as carriers of cargo proteins
to their desired locations in the cell. The Tat-derived PT
peptide used in this study has been shown to be highly
eﬃcient for the delivery of diverse proteins intomammalian
cells both in vitro and in vivo. In addition, the precise dose of
transducible proteins is more readily determined, com-
pared to viral delivery or DNA transfection. Indeed, it
is usually quite diﬃcult to control the concentration of
eﬀective proteins expressed in cells when the proteins are
introduced via DNA transfection or viral delivery.
In this study, we employed the well-characterized 11
amino acid PTD derived from the HIV-1 Tat transcrip-
tional activator to produce transducible TFs for targeted
regulation of an endogenous human gene. The eﬃciency
of PTD-mediated protein delivery is highly dependent on
many factors, including but not limited to, cargo proteins,
target cells and the PTD itself (4). Tachikawa et al. (26)
showed that artiﬁcial transcription factors fused to the
Tat-derived PTD were eﬃciently delivered into mamma-
lian cells in vitro. To the best of our knowledge, the study
described herein is the ﬁrst report in which artiﬁcial TFs
were transduced into mammalian cells in vivo. Although
many ZF-TFs have been designed to target speciﬁcally
various mammalian genes, only one factor has been
tested in animal studies thus far. Rebar et al. (16) reported
that ZF transcriptional activators that target the VEGF-A
gene are able to elicit blood vessel formation in rodent
models, when delivered via naked DNA transfection or
viral vectors. An expression plasmid encoding this
VEGF-A transcriptional activator is now being tested in
clinical studies in the US for the treatment of cardiovascu-
lar disease (27). Here, we report on a second ZF-TF whose
eﬃcacy has been demonstrated in animal models. Our
ZF-TF downregulated the expression of VEGF-A and
functioned as an anticancer agent in mouse xenograft
experiments.
Unlike the ZF-TFs described in this report, the artiﬁcial
TFs used by others were constructed by introducing muta-
tions at key positions in given framework sequences of
ZFPs. These mutations are likely to lead to the production
of proteins that induces an immune response, especially
when the proteins are tranduced in vivo. Our ZF-TFs con-
tain naturally occurring ZFs derived from sequences in the
human genome and thus are less likely to elicit an immune
response (24). The use of a PTD derived from a human
protein (6) instead of the viral Tat PTD to make
transducible TFs would also help to minimize the host
immune response.
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